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ABSTRACT
Gene expression is regulated at the transcriptional
and post-transcriptional levels. Therefore, in order
to achieve a high level of silencing, which includes
minimizing any residual expression of a target gene,
suppression at both the transcriptional and post-
transcriptional levels is required. In this study, we
describeanewmethod forhighly efficient gene silen-
cing that combines zinc finger protein-mediated tran-
scriptional repression and small interfering RNA
(siRNA)-mediated inhibition of post-transcriptional
events. To measure the amount of gene expression
under various conditions, we used a luciferase
reporter gene that was driven by a variety of pro-
moters, including that of the human vascular
endothelial growth factor-A (VEGF-A) gene. We also
measured expression of the endogenous VEGF-A
gene. Inhibition of gene expression by each of the
two individual technologies was effective, but in-
depth analyses revealed residual expression of the
target gene. The combination of specific zinc finger
transcription factors and siRNAs greatly enhanced
the silencing of the human VEGF-A gene, not only
when cells were grown in the presence of normal
amounts of oxygen but also under conditions of hyp-
oxic stimulation. These results suggest that a bi-level
approach to the silencing of VEGF-A expression may
be clinically beneficial as part of a cancer treatment
protocol.
INTRODUCTION
A fundamental goal of scientists working in this post-genomic
age is the ability to tightly regulate the expression of speciﬁc
genes. Designer zinc ﬁnger transcriptional regulatory proteins
and RNA interference (RNAi) are two key technologies that
offer powerful means of achieving this goal.
Gene expression is regulated by two related yet separate
events: (i) transcription of the gene into an RNA molecule
and(ii) post-transcriptionalregulationthatincludesprocessing
of this precursor RNA to form a mature messenger RNA
moleculeandtranslationintoaprotein.Zincﬁngertranscription
factors regulate expression at the level of transcription, while
RNAi functions during post-transcriptional processing. In
1998, Fire et al. (1) reported that, in the worm Caenorhabditis
elegans, double-stranded RNA (dsRNA) molecules inhibit the
translationoftargetmRNAsmoreefﬁcientlythandoindividual
single-stranded RNAs and the resulting phenotype is appar-
ently inheritable by progeny. The exogenous dsRNA is pro-
cessed into 19- to 23-nt small interfering RNAs (siRNAs) by
the worm enzyme Dicer. Incorporation of these siRNAs into
the RNA-induced silencing complex (RISC) is required for the
post-transcriptional recognition and subsequent degradation of
mRNAs that are homologous to the siRNAs (2). The RNAi
phenomenon was observed for a large number of genes either
byusingdsRNAs that arecomplementarytothetarget mRNAs
orbyscreeningRNAilibrariesinC.elegans(1,3,4),Drosophila
(5), plants (6,7) and mammalian cells (8–10), including the
human embryonic kidney cell line HEK293 (10). RNAi-
mediated gene silencing at the transcriptional level was repor-
ted in limited studies with plants (11–13) and Drosophila (14),
but this phenomenon has not been clearly observed in mam-
maliancells.ThusthemajorfunctionofsiRNAsinmammalian
cells appears to be to silence gene expression at the post-
transcriptional level. RNAi is highly speciﬁc, as shown in
genome-wide gene expression proﬁles obtained during inhibi-
tionofgreenﬂuorescentproteinexpression(15)andinisoform-
speciﬁc suppression of mouse vascular endothelial growth
factor-A (VEGF-A) mRNA (16) by siRNAs.
The C2-H2 class of zinc ﬁnger proteins (ZFPs) constitutes
one of the most common DNA binding motifs found in
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on which to generate zinc ﬁnger transcription factors with
novel DNA binding speciﬁcities (17). We and several other
groups have characterized extensively the modularity and spe-
ciﬁcity of naturally occurring and artiﬁcially engineered zinc
ﬁnger domains (18–22). Advancements in ZFP technology
have allowed the production of artiﬁcial ZFPs by in vitro
screening of randomized composite zinc ﬁnger domains
(19–21) or by mixing and matching pre-characterized zinc
ﬁnger domains (22). Thus we now have the capability to
design speciﬁc ZFPs that bind with high afﬁnity to selected
DNA sequences and activate or repress target gene transcrip-
tion, when fused to a transcriptional activation or repression
domain, respectively. The ability of ZFPs to selectively regu-
late transcription of endogenous genes has been reported for
mammalian cells (22–26), plants (27), yeast (28) and eubac-
teria (unpublished data), and accumulating evidence clearly
indicates that the ZFP technology is one of the most versatile
tools for upregulating or downregulating target gene transcrip-
tion (23,24). The modular nature of ZFPs has facilitated the
generation of libraries that encode diverse ZFP-transcription
factors (ZFP-TFs) that interact with speciﬁc DNA sequences
and regulate gene transcription on a genome-wide scale. In
addition, recent studies have shown that ZFP transcription
factor libraries can be used to induce particular phenotypes
and to identify the genes that are responsible for the phenotype
of interest (28,29).
In this paper, we show that ZFP technology and RNAi can
be combined to obtain highly efﬁcient silencing of the VEGF-
A gene. VEGF-A is an angiogenic factor that is crucial for both
the formation of normal blood vessels and the vascularization
and growth of tumors. VEGF-A gene expression is stimulated
by hypoxic conditions, which manifest in the tumor cells
along with tumor growth. Suppression of VEGF-A expression
by both methods simultaneously almost completely ablated
hypoxia-stimulated VEGF induction, suggesting that these
methods might be beneﬁcial in the treatment of cancers.
MATERIALS AND METHODS
Plasmid constructs for ZFP-TFs, reporter genes and
short hairpin RNAs
The cloning of ZFP-TFs pF268, pF121, pF109 and pF435
is described elsewhere (22). The amino acid sequences of
four ZFPs are: NH3
+-YVCDVEGCTWKFARSDELNRHKK-
RHTGEKPFQCKTCQRKFSRSDHLKTHTRTHTGEKPYV-
CDVEGCTWKFARSDELNRHKKRH-CO2
  [F268], NH3
+-
YKCEECGKAFRQSSHLTTHKIIHTGEKPYKCMECGKA-
FNRRSHLTRHQRIHTGEKPFQCKTCQRKFSRSDHLKTH-
TRTH-CO2
  [F121], NH3
+-YVCDVEGCTWKFARSDELNR-
HKKRHTGEKPYKCPDCGKSFSQSSSLIRHQRTHTGEKP-
YKCEECGKAFRQSSHLTTHKIIHTGEKPYICRKCGRGFS-
RKSNLIRHQRTH-CO2
  [F109] and NH3
+-YKCGQCGKFY-
SQVSHLTRHQKIHTGEKPFQCKTCQRKFSRSDHLKTHT-
RTHTGEKPYKCGQCGKFYSQVSHLTRHQKIH-CO2
 
[F435]. To add a transcriptional repression domain [Kru ¨ppel-
associated box A (KRAB), a segment of the KRAB-A domain
from the rat kidney transcription factor kid-1] to an engineered
ZFP domain, the DNA encoding the assembled ZFP was sub-
cloned into pLFD-KRAB (Figure 1A) using the EcoRI and
NotI restriction sites, resulting in a construct that encoded the
following fusion protein: hemagglutinin tag (HA)–nuclear
localization signal (NLS)-ZFP-KRAB. The KRAB repression
domain used in these studies contains 63 amino acids (NH3
+-
VSVTFEDVAVLFTRDEWKKLDLSQRSLYREVMLE-
NYSNLASMAGFLFTKPKVISLLQQGEDPW-CO2
 )t h a t
constitute the minimal segment that retains transcriptional
repressor activity (obtained from the pTet-tTS vector,
Clontech, Palo Alto, CA, USA).
The luciferase reporter construct pGL-TA-ZFPBS and the
plasmid encoding the transcriptional activator Gal4-VP16
were described elsewhere (30), except for the following
minor modiﬁcations to the reporter construct. Brieﬂy,
sequences from  124 to  110 from the transcriptional initi-
ation site of pGL3-TATA/Inr+18 (30) were deleted with a
KpnI/MluI digest, and the resulting vector was blunt-end
ligated. A BglII site was inserted by substituting an A for a
G at position +12 from the site of transcription initiation to
create pGL-TA (Figure 1B). pGL-TA was cleaved with BglII
and HindIII, and zinc ﬁnger binding sequences (Table 1) were
inserted. To create the dsDNA encoding the zinc ﬁnger bind-
ing sites, complementary oligonucleotides were synthesized
and hybridized by gradual cooling from 90 Ct o2 5  Ci n
100 mM potassium acetate, 30 mM HEPES KOH pH 7.4
and 2 mM magnesium acetate.
The native human VEGF-A promoter DNA ( 950 to +450
from the transcription initiation sequence) was ampliﬁed by
subjecting human genomic DNA to the PCR using speciﬁc
primers. The ampliﬁed human VEGF-A promoter DNA was
then cloned into the KpnI and XhoI restriction sites of pGL3,
yielding pGL-VEGF (Figure 1C). The primer sequences used
for VEGF-A promoter cloning were: 50-CGG GGT ACC CCC
TCC CAG TCA CTG ACT AAC-30 (forward) and 50-CCG
CTC GAG TCC GGC GGT CAC CCC CAA AAG-30
(reverse).
A vector-based short hairpin RNAs (shRNA) expression
system was used to endogenously express shRNA in mamma-
lian cells. An shRNA that binds to and induces the degradation
of endogenous VEGF-A mRNA in HEK293 cells (thereby
repressing expression of the VEGF-A protein) was prepared
as follows. Several DNA sequences that encode VEGF-A
shRNAs were designed, on the basis of the sequence of
VEGF-165 mRNA, to target multiple sites of the transcript
(GenBank accession no. GI 19909064) and chemically syn-
thesized. The sequences for two representative shRNAs are
shown in Table 2. The DNA sequences were cloned into the
BamHI/HindIIIrestrictionsiteofthepSilencer
TMhygrovector
(Ambion, Austin, TX, USA), and the resulting shRNA exp-
ression plasmids were then transfected into HEK293F
cells (Life Technologies, Carlsbad, CA, USA), which permit
a high efﬁciency of transfection.
siRNA synthesis and hybridization
Antisense RNA oligonucleotides that were complementary to
the translation start site of ﬁreﬂy luciferase mRNA (+153 to
+173) (siRNA-luc) were chemically synthesized by Synthetic
Genetics (San Diego, CA, USA). The sequences of the sense
and antisense RNAs were 50-CUUACGCUGAGUACUUC-
GATT-30 (sense) and 50-UCGAAGUACUCAGCGUAAG-
TT-30 (antisense), as was published by Elbashir et al. (10).
e74 Nucleic Acids Research, 2005, Vol. 33, No. 8 PAGE 2 OF 10The double-stranded siRNA molecules were prepared by brief
boiling and slow cooling, and were then stored at  80 C until
they were used for transfections.
Cell culture and transfection of 293 cells
HEK293 cells (ATCC, Manassas, VA, USA) were maintained
in DMEM supplemented with 100 U/ml penicillin, 100 mg/ml
streptomycin and 10% fetal bovine serum (FBS) (all from Life
Technologies, Carlsbad, CA, USA). For the transient trans-
fections, 293 cells (2 · 10
4 cells/well) were pre-cultured for
24 h in poly D-lysine-coated 96-well culture plates (Becton
Dickinson, Franklin Lakes, NJ, USA) that contained 100 mlo f
the medium described above but deprived of antibiotics. For
some experiments (e.g. mRNA analysis), 10
5 cells/well were
cultivated in 24-well culture plates. Unless otherwise indic-
ated, the 293 cells were transfected with a nucleic acid mixture
that totaled 0.15 mg (for 96-well culture plates) or 0.5 mg (for
24-well culture plates).
The nucleic acid mixtures included various plasmids:
effector plasmids that encode ZFPs (Figure 1A), reporter
plasmids encoding ﬁreﬂy luciferase (Figure 1B) and internal
Figure 1. Constructs used in the experiments described herein. (A) Expression vector constructs for ZFP-KRAB artificial transcriptional repressors. Zinc finger
domains were designed and assembled on a p3 vector that included the CMV promoter, HA-epitope and NLS. The resulting zinc finger expression vectors pF268,
pF121 and pF435 consist of three zinc finger domains, and pF109 consists of four zinc finger domains. DNA binding domains F268, F121, F109 and F435 were
subcloned into pLFD-KRAB, yielding pF268-KRAB, pF121-KRAB, pF109-KRAB and pF435-KRAB. The amino acid sequence of the KRAB transcriptional
repressiondomainisdescribedinMaterialsandMethods.FD,functionaldomain.(B)FireflyluciferasereporterconstructswiththeTATA-minimalpromoter(pGL-
TA) and five copiesof the Gal4-bindingsequence (5 · Gal4BS) (pGL-TA-ZFPBS). A single copy of the ZFP bindingsequences was introducedat the +18 position
relativetothetranscriptionalinitiationsite(Inr).ThebindingsequencesforeachZFParedescribedinTable1.pGL-SV40-F268BSorpGL-CMV-F268BSarefirefly
luciferase reporter constructs that contain an SV40 promoter or a CMV promoter, respectively. At the 50 end of the promoter, three copies of a zinc finger binding
sequenceforF268wereintroduced.ThebindingsequenceforF268isdescribedinTable1.(C)pGL-VEGFisaluciferasereporterconstructthatcontainsthenative
human VEGF-A promoter sequences (from  950 to +450 relative to transcriptional initiation site). Binding sequences for F121 and F109 are present at positions
+434 and  536, respectively.
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WI, USA) and plasmids that encode the transcriptional activ-
ator Gal4-Vp16 (30). In some experiments, the indicated
amounts of siRNA or plasmids that encode shRNA were
added to the DNA mixtures prior to Lipofectamine complex
formation. Transfection was performed with the Lipofect-
amine Plus transfection kit (Life Technologies, Carlsbad,
CA, USA) according to the manufacturer’s instruction.
Cells were further incubated at 37 C for 48 h in a humid
atmosphere with 5% CO2.
To measure luciferase expression driven by the native
VEGF-A promoter, the Lipofectamine Plus transfection kit
was used to transfect 293 cells (2 · 10
4) with the pGL-
VEGF reporter and either F121-KRAB or pF109-KRAB at
a 1:1 molar ratio (ﬁnal DNA concentration: 100 ng).
Luciferase assay
After incubation at 37 C for 48 h after transfection, cultured
cells were washed twice with phosphate-buffered saline (PBS)
and mixed with passive lysis buffer (30 ml; Promega, Madison,
WI, USA). Fireﬂy and Renilla luciferase activities in the cell
lysates were measured in dual wavelength in a TD-20/20
luminophotometer (Turner Designs, Sunnyvale, CA, USA)
after sequential addition of the LAR II reagent (40 ml), stop
buffer (40 ml) and the Glo reagent to the lysates (8 ml). The
Dual-luciferase reporter assay kit (E1960) was purchased from
Promega.
Quantification of VEGF-A mRNA
Because they permit a very high efﬁciency of transfection,
293F cells (Gibco Life Technologies, Carlsbad, CA, USA),
rather than HEK293 cells, were used to analyze the extent of
repression of endogenous VEGF-A expression. Cells were
maintained under the same conditions used for the HEK293
cells except that non-essential amino acids (0.1 mM; Life
Technologies, Carlsbad, CA, USA) were added to the culture
media.
For the RT–PCR analysis, 10
5 293F cells/well were pre-
cultured, at 37 C in a humid atmosphere containing 5% CO2,
for 24 h in 24-well plates containing culture medium (0.5 ml;
supplemented with 10% FBS but deprived of antibiotics). The
cells were then transfected with DNA using a Lipofectamine
Plus transfection kit (Life Technologies). Brieﬂy, a total of
0.5 mg of plasmid DNA (i.e. a plasmid that encodes a ZFP,
with or without plasmids encoding shRNAs) were mixed with
4mlofthePlusreagentin25 mlDMEM,andthen another25 ml
of DMEM containing 2.5 ml of Lipofectamine reagent was
added to the mixture. The culture growth medium was
removed from the cells and replaced with 200 ml of fresh
serum-free DMEM prior to transfection. After 15 min of
incubation, the 50-ml mixtures described above were then
added to each well of the culture plate. Six hours after trans-
fection, DMEM containing 20% FBS (250 ml) was added to
each culture well, and the cells were grown for an additional
48 h. The cells and culture supernatants were harvested for
RT–PCR analysis and an enzyme-linked immunosorbent
assay (ELISA).
The cell pellets were lysed in Trizol reagent (Life Techno-
logies) and stored at  80 C until total RNA was extracted.
RNA was extracted from the Trizol-lysates according to the
manufacturer’s instructions (Life Technologies). The reverse
transcription reactions were performed with 4 mg of total RNA
using oligo-dT as the ﬁrst-strand synthesis primer for mRNA
Table 1. Zinc finger proteins and their target DNA sequences
ZEP Amino acid sequence of a-helix
a Target DNA sequences
F268 RSDELNR–RSDHLKT–RSDELNR 50-GCG TGG GCG-30
30-CGC ACC CGC-50
F109 RSDELNR–QSSSLIR–QSSHLTT–RKSNLIR 50-GAG CGA GCA GCG-30
30-CTC GCT CGT CGC-50
F121 QSSHLTT–RRSHLTR–RSDHLKT 50-TGG GGG TGA-30
30-ACC CCC ACT-50
F435 QVSHLTR–RSDHLKT–RRSHLTR 50-GGG CGG GGA-30
30-CCC GCC CCT-50
Bold letters indicate putative DNA-contacting residues.
aThe amino acid sequences ( 1 to 6th residues) in a-helices of each zinc finger domain using the 1-letter code.
Table 2. Oligonucleotide sequences used for the cloning of shRNA expression plasmids and the sequences of the resulting shRNAs
shRNA Oligonucleotide sequence
shVEGF+64 50-GATC CCGTGGTCCCAGGCTGCACCCC TTCAAGAGA GGGGTGCAGCCTGGGACCACTTTTTTGGAAA-30a
50-AGCT TTTCCAAAAAAGTGGTCCCAGGCTGCACCCC TCTCTTGAA GGGGTGCAGCCTGGGACCACGG-30a
50-GUGGUCCCAGGCUGCACCCC UUCAAGAGA GGGGUGCAGCCUGGGACCACUUUUUU-30b
shVEGF+338 50-GATC CCGGCCAGCACATAGGAGAGA TTCAAGAGA TCTCTCCTATGTGCTGGCC TTTTTTGGAAA-30a
50-AGCT TTTCCAAAAAAGGCCAGCACATAGGAGAGA TCTCTTGAA TCTCTCCTATGTGCTGGCCGG-30a
50-GGCCAGCACAUAGGAGAGA UUCAAGAGA UCUCUCCUAUGUGCUGGCCUUUUUU-30b
Bold letters indicate BamHI and HindIII restriction site overhangs.
Italic letters indicate the loop structure.
Underlined are RNA sequences complementary to the target sites.
aThe oligonucleotide sequences for cloning of shRNAs.
bThe expected shRNA sequence.
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transcriptase provided in the Superscript ﬁrst-strand synthesis
system(LifeTechnologies).ToanalyzemRNAquantities,1ml
of the ﬁrst-strand cDNAs generated from the RT reactions
were ampliﬁed using VEGF-speciﬁc primers [50-GTG CAT
TGG AGC CTT GCC TTG-30 (forward) and 50-ACT CGA
TCT CAT CAG GGT ACT C-30 (reverse)]. The speciﬁc
VEGF-A mRNA amounts were normalized to the glyceralde-
hyde 3-phosphate dehydrogenase (GAPDH) mRNA quantities
calculated by speciﬁc ampliﬁcation using GAPDH-speciﬁc
primers [50-CCA TGT TCG TCA TGG GTG TGA-30 (for-
ward) and 50-CAT GGA CTG TGG TCA TGA GT-30
(reverse)]. Ampliﬁcation of VEGF-A-speciﬁc and GAPDH-
speciﬁc cDNAs were monitored and analyzed in real-time
with a Quantitect SYBR kit (Qiagen, Valencia, CA, USA)
and a Rotorgene 2000 real-time cycler (Corbett Research,
Mortlake, NSW, Australia), and were quantiﬁed using serial
dilution of the standards included in the reactions.
Quantification of secreted VEGF-A protein
The HEK293 cell culture supernatants were centrifuged for
5 min to remove cells and cell debris. VEGF-A protein that
accumulated in the culture medium (100 ml each) and dilutions
of a recombinant human VEGF-A protein standard were ana-
lyzed using sandwich ELISA, wherein the supernatant of the
culture was incubated with anti-human VEGF-A antibody
(AF-293-NA; R&D Systems, Minneapolis, MN, USA), biot-
inylated anti-human VEGF-A antibody (BAF293; R&D
systems) and streptavidin alkaline phosphatase (SA110;
Chemicon, Temecula, CA, USA). The antigen–antibody com-
plex was then incubated with p-nitrophenyl phosphate (Sigma,
St Louis, MO, USA) dissolved in pNPP buffer (Chemicon;
ES011). VEGF-A concentrations in the samples were deter-
mined from the absorbance at 405 nm, which was measured
with a POWERWAVE(tm) X340 (Bio-TEK Instrument Inc.,
Richmond, VA, USA).
RESULTS
Suppression of reporter gene expression by
ZFP-TFs, siRNAs or both
In order to examine whether a ZFP transcriptional repressor
and siRNA, each of which targets the same gene, could func-
tion additively or synergistically to suppress its expression, we
used the ﬁreﬂy luciferase reporter gene under the control of
various promoters. First, we tested a well-characterized syn-
thetic promoter (termed TATA) that contains the adenovirus
major late promoter TATA box and the murine terminal
deoxynucleotidyltransferase initiator (30). So that the effects
of a ZFP-TF or siRNA on activated transcription could be
studied, a set of ﬁve GAL4 binding sites was included
upstream of the TATA promoter to generate pGL-TA. For
some experiments, as shown in Figure 1B and Table 1, a
9-bp ZFP binding site (50-GCG TGG GCG-30) was incorpor-
ated downstream of the murine terminal deoxynucleo-
tidyltransferase initiator element (pGL-TA-F268BS). The
ZFP used in this experiment (termed F268) is a derivative
ofthe well-deﬁnedmouseZFPzif268,inwhich the thirdﬁnger
of zif268 was replaced with a human zinc ﬁnger domain
referred to as RDER (22). F268 is functionally equivalent
to the zif268 zinc ﬁnger peptide in terms of its DNA-
binding afﬁnity and speciﬁcity (data not shown). This ZFP
was fused to the KRAB transcriptional repression domain, and
the plasmid that expressed the resulting ZFP-TF was desig-
nated pF268-KRAB (Figure 1A).
HEK293 cells were co-transfected with pF268-KRAB and
an expression plasmid encoding the GAL4-VP16 (30) protein
(a transcriptional activator), together with the luciferase
reporter plasmid containing the appropriate ZFP binding
site (pGL-TA-F268BS). The ZFP-TF (F268-KRAB) showed
a  10-fold (–0.7) repression (i.e.  90%) of GAL4-VP16-
activated transcription from the synthetic promoter. We also
transfected 293 cells with pGL-TA-F268BS and with chem-
ically synthesized antisense RNA oligonucleotides that are
complementary to the translation start site of ﬁreﬂy luciferase
mRNA (siRNA-luc). The siRNA-luc oligonucleotides showed
an  20-fold (–2.1) repression (i.e. 95%) of GAL4-VP16-
activated transcription of the luciferase gene.
Although each reagent (the ZFP-TF and siRNA) on its own
was effective at repressing transcription, neither the ZFP-TF
nor siRNA-luc was able to achieve complete gene silencing
under our experimental conditions. In order to achieve com-
plete suppression of gene expression, we transfected 293 cells
with both siRNA-luc and pF268-KRAB, along with the
reporter plasmid (pGL-TA-F268BS) and the GAL4-VP16
expression plasmid. Co-transfection of the ZFP-TF-
encoding plasmid and siRNA-luc resulted in a dramatic
increase in the extent of repression over what was observed
with each of the reagents individually. For example, in the
presence of siRNA-luc and in the absence of the ZFP-TF
expression plasmid, an  20-fold repression of reporter gene
expression was observed relative to the control conditions,
while in the presence of both reagents, an  140-fold (–15)
(99.3%) repression of reporter gene expression was detected
relative to the control (Figure 2A).
We also tested the SV40 early promoter and the cytomega-
lovirus (CMV) immediate early promoter to examine whether
ZFP-TFs and siRNAs can repress gene expression synergist-
ically at naturally occurring promoters as well as at the syn-
thetic promoter. As shown in Figure 1B, the 9-bp ZFP (F268)
binding sequence was incorporated upstream of the SV40 and
CMV promoters. Human 293 cells were co-transfected with
the ZFP-TF-encoding plasmid (pF268-KRAB), siRNA-luc or
both, together with the SV40 promoter-driven and CMV
promoter-driven luciferase reporter constructs. The GAL4-
VP16 expression plasmid was not included in these experi-
ments. The ZFP-TF alone showed a moderate 5.0-fold (80%)
repression, and siRNA alone showed 4.8-fold (79%) repres-
sion of expression from the SV40 promoter relative to the
control. Co-transfection of siRNA and the ZFP-TF-
encoding plasmid yielded 21-fold (95%) repression of expres-
sion from this promoter (Figure 2B) relative to the control.
Comparable results were observed with the CMV promoter
construct; the ZFP-TF or siRNA alone showed 4.0-fold (75%)
or 4.2-fold (76%) repression relative to the control, respect-
ively, whereas the combination of the ZFP-TF and siRNA
resulted in a much stronger 15-fold (93%) repression of
expression from the CMV promoter relative to the control
(Figure 2C). Figure 2D shows a representation of the dose-
dependent synergistic effect on luciferase expression of
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reporter construct (CMV).
To conﬁrm that the observed repression of luciferase
reporter gene expression by the ZFP-TF was dependent on
the ZFP-TF target DNA binding sequence, we co-
transfected 293 cells with the ZFP-TF-encoding plasmid
(pF268-KRAB) in combination with one of three reporter
plasmids: pGL-TA-F268BS, pGL-TA-F121BS or pGL-TA-
F109BS, each of which contains different ZFP binding
sequences as shown in Table 1. Repression of reporter gene
expression by F268-KRAB was observed only when the
reporter contained the matching target ZFP binding site
(data not shown). We also have conﬁrmed that siRNA-luc
speciﬁcally silenced reporter gene expression with our pro-
moter systems; siRNA-luc did not repress luciferase expres-
sion when the siRNA target sequence was mutated (data not
shown). These data indicate that the suppressive activities of
the ZFP-TF and siRNA used in this series of the experiments
are speciﬁc for the well-characterized targets of the two
reagents.
The ZFP-TF/siRNA combination strengthens silencing
of a VEGF-A promoter-driven reporter gene
We sought to assess the synergistic gene silencing effect of
ZFP-TFs and siRNAs using a luciferase reporter plasmid that
contained the native human VEGF-A promoter region ( 950
to +450 relative to transcriptional initiation site). We used two
ZFP constructs (termed F121 and F109, which are composed
of 3 and 4 human zinc ﬁnger domains, respectively) designed
to recognize speciﬁc sequences in the VEGF-A promoter. We
have previously shown that these ZFPs, when fused to a tran-
scriptional activation domain, stimulate transcription of the
endogenous VEGF-A gene as well as a reporter gene under
the control of the VEGF-A promoter (22). Here, we sought to
generate and test artiﬁcial transcription factors that suppress
VEGF-A gene expression by fusing these ZFPs to the KRAB
domain (Figure 1A). HEK293 cells were co-transfected with a
luciferase reporter plasmid containing the VEGF-A promoter
(pGL-VEGF) and either the F121-KRAB or the F109-KRAB
expression plasmid. The ZFP-TFs, F121-KRAB and F109-
KRAB, individually suppressed reporter luciferase activity
8.7-fold (–2.0) and 6.1-fold (–1.2), respectively (Figure 3A
and B; see the ( ) siRNA groups) compared with the control
[( ) siRNA and ( ) ZFP]. siRNA (siRNA-luc) alone also
yielded a moderate level of gene silencing, i.e. 4.5-fold
(–1.0) suppression of the same reporter gene (pGL-VEGF)
relative to the control [( ) siRNA and ( ) ZFP]. As expected,
dramatic suppression of luciferase expression was observed
when the ZFP-KRAB plasmids were co-transfected with
siRNA. Speciﬁcally, F121-KRAB and F109-KRAB yielded
an  61-fold (–12) (i.e.  98.3%) and an  20-fold (–3.2)
( 94.9%)repressionofVEGFpromoter-controlledexpression
of the luciferase reporter gene, relative to the control, when
combined with siRNA.
It is interesting to note that, for all four promoters we tested,
the fold-repression of the reporter gene with both the ZFP-TF
and siRNA is approximately equal to the product of the fold-
repression with the ZFP-TF alone and that with siRNA alone.
For example, siRNA or the ZFP-TF gave 4.2-fold or 4.0-fold
repression of expression from the CMV promoter(pGL-CMV-
F268BS), respectively, whereas the two reagents in combina-
tion gave  15-fold repression (Figure 2C). This observation
implies that transcriptional repression by ZFP-TFs and gene
silencing with siRNA occur by independent mechanisms. We
expect that ZFP-TFs in combination with siRNAs should give
much stronger repression of most, if not all, target genes than
do ZFP-TFs or siRNAs alone.
RNAi and ZFP-TFs synergistically suppress
endogenous VEGF-A gene expression
To assess whether RNAi and ZFP-TFs are capable of silencing
endogenous human VEGF-A gene expression, we tested
Figure 2. Regulation of luciferase with a combination of siRNAs and F268-KRAB. HEK293 cells were transfected with 50 ng (+) of siRNA, 15 ng (+)o f
pF268-KRAB,neithereffector( )orbotheffectorstogetherwith(A) thepGL-TA-F268BSreporter(15ng)plustranscriptionalactivator Gal4-VP16(68.5ng),(B)
thepGL-SV40-F268BSreporter(15ng)or(C)thepGL-CMV-F268BSreporter(15ng).TheRenillaluciferaseexpressionplasmid(1.5ngpRL-SV40)wasaddedin
equal amounts to the nucleic acid mixtures.The total amountsof DNA and RNA were brought to 150 ng by the addition of empty vector. Luciferase activities were
measured 48 h post-transfection. Fold repression values were obtained after normalization of firefly luciferase activity to Renilla luciferase activity then compared
with values obtained from control cultures transfected with empty vectors and reporters [pF268-KRAB ( ), siRNA ( )]. Results are the mean values and standard
errors of three independent experiments. (D) Simultaneous representation of the dose effects of the ZFP-TF and siRNA in the repression of luciferase activity
measuredin 293cell culturesco-transfectedwithvaryingamountsofplasmidsthatencodea ZFP-TF(0–15ng)orsiRNA(0–50ng)togetherwiththereporterpGL-
CMV-F268BS. Fold repression values were obtained after normalization of firefly luciferase activity to Renilla luciferase activity then compared with values
obtainedfromcontrolcultures[0ngpF268-KRAB+0ngsiRNA].Thetotalamountofnucleicacidwascalibratedtoafinalamountof100ngwiththeemptyvector
pLFD-KRAB. Results are the mean values of three independent experiments.
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VEGF promoter. Unfortunately, F121-KRAB and F109-
KRAB, which showed strong repression in the luciferase
reporter assay, were not able to signiﬁcantly suppress the
expression of the endogenous VEGF gene (data not shown).
These ZFP-TFs may not bind to the target sites in the chro-
matin state in cells. Thus we used another ZFP, i.e. F435, for
the regulation of the endogenous gene. F435 is the DNA
binding moiety of a ZFP-TF that was shown to activate
VEGF-A expression in human cells (22). In the current
study, F435 was fused with the KRAB transcriptional repres-
sion domain. Snowden et al. (31) reported previously that a
ZFP-TF composed of engineered zinc ﬁnger domains and
the KRAB domain was successful in suppressing VEGF-A
expression in 293 cells and a highly tumorigenic glioblastoma
cell line, indicating that ZFP-mediated VEGF-A suppression
has therapeutic potential for cancer treatment.
For convenience of design and manipulation, we used an
expression vector system that yields shRNA that induces
VEGF-A-speciﬁc RNAi in mammalian cells. A series of U6
promoter-driven shRNAs were designed to target human
VEGF-A mRNA, the most potent being shVEGF+64 and
shVEGF+338, which encode RNAs that can form partial
double-stranded hairpin structures. shVEGF+64 and
shVEGF+338 contain 21-nucleotide sequences that are com-
plementary to VEGF-A mRNA beginning at positions +64
and +338 within coding region, respectively (Table 2).
We found that endogenous VEGF-A mRNA quantities
measured by real-time RT–PCR were reduced up to 4.0-
fold (75% reduction) by F435-KRAB (400 ng plasmid) and
3.5-fold (71% reduction) by shVEGF+64 (100 ng plasmid),
compared with controls (Figure 4A). Although both reagents
repressed VEGF-A expression signiﬁcantly, neither did so
completely, even if the amounts of transfected plasmids
Figure 3. SynergisticinhibitoryeffectofZFP-TFsandsiRNAsonluciferaseproductiondrivenbythenativehumanVEGFpromoter.Twohundredandninety-three
cellsweretransfectedwithaluciferasereporterconstructthatcontainedthenativehumanVEGF-Apromotertogetherwitheither(A)30ngofpF121-KRAB(+),50ng
of siRNA (+) or both, or (B) 30 ng pF109-KRAB (+), 50 ng siRNA (+) or both. Fold repression values were obtained by comparing repressed amounts of luciferase
activitywiththatmeasuredinculturesthathadbeentransfectedwithemptyvector( / )andreporter(pGL-VEGF)only[0ngpF121-KRABorpF109-KRAB,0ng
siRNA]. Results are the mean values and standard errors of three independent experiments.
Figure 4. Synergistic repression of endogenous VEGF-A at the mRNA and protein level. 293F cells (10
5 cells/24-well plate) were co-transfected with increasing
amountsofaplasmidthatencodesaZFP-TF[pF435-KRAB;0,200,400ng]andanshRNA-encodingplasmid[shRNA+64;0( ),100ng(+)].TotaltransfectedDNA
wascalibratedtoafinalamountof500ngwiththeadditionofthepLFD-KRABemptyvector.VEGF-AmRNAwasanalyzedbyRT–PCRusingspecificprimers(see
Materials and Methods). The amounts of VEGF mRNA were normalized to the amounts of GAPDH mRNA from the same reverse transcription product, then fold
repression values were calculated by dividing normalized values from control cultures by that of effector-treated cultures (A). Results are the mean values and
standard errors of three independent experiments. Also shown are simultaneous representations of the fold repression of secreted VEGF-A protein obtained from
293Fcellculturesthathadbeenco-transfectedwithvariouscombinationsofZFP-encodingplasmidsandeithershRNA+64(B)orshRNA+338(C)andincubatedfor
72 h. Results are the mean values of three independent experiments.
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plasmids encoding F435-KRAB and shVEGF+64 into 293
cells gave an 18-fold (94%) reduction in the level of
VEGF-A mRNA compared with controls (Figure 4A). The
residual VEGF-A mRNA might be expressed from non-
transfected cells, which constituted  5–10% of the popula-
tion, as calculated from lacZ staining of parallel cells after
transfection (data not shown). This suggests that
co-transfection of the ZFP-TF and siRNA leads to almost
complete silencing of the VEGF-A gene in 293 cells.
Next, we performed an ELISA using human VEGF-speciﬁc
antibodies to quantify the amount of VEGF-A protein present
in the culture media. When cells were transfected with the
F435-KRAB expression plasmid, the VEGF-A concentration
in the media was decreased in a dose-dependent manner
(Figure 4B and C; see the shRNA: 0 ng groups). Likewise,
the plasmids expressing shRNAs (shVEGF+64 and
shVEGF+338) individually showed dose-dependent suppres-
sion of VEGF-A protein production (Figure 4B and C; see the
pF435-KRAB: 0 ng groups). The strongest repression of
VEGF-A protein production with shRNA alone was merely
2.4-foldrelativetocontrolsunderourexperimentalconditions.
These results were in agreement with the amount of VEGF-A
mRNA present, as analyzed by RT–PCR experiments.
We then assessed the effect of both the ZFP-TF and shRNA
on VEGF-A protein production. Cells were transfected with
the two plasmids encoding F435-KRAB and shRNA, and the
VEGF-A level was measured by ELISA. A dose-dependent
reduction in VEGF-A protein concentration was detected in
the presence of increasing amounts of both the F435-KRAB
and shRNA expression plasmids; inhibition of VEGF-A secre-
tion reached a maximum of 83% (shRNA+64 plasmid, 100 ng
and ZFP-TF plasmid, 200 ng) or 91% (shRNA+338 plasmid,
100 ng and ZFP-TF plasmid, 200 ng), compared with culture
supernatants obtained from cells transfected with the control
parental vector (Figure 4B and C). The level of inhibition
reached by the combined reagents constitutes nearly complete
silencing when we take into account the transfection efﬁciency
[ 90–95% under our experimental conditions (data not
shown)].
The combination of ZFP-TFs and shRNAs inhibits
hypoxia-induced VEGF-A activation
We next performed a set of experiments to determine whether
the VEGF-A production-suppressing shRNAs and ZFP-TFs
could down-regulate VEGF-A expression in the presence of
the hypoxia-inducing agent cobalt chloride (CoCl2), a strong
stimulator of VEGF-A expression in cultured cells. Cells were
transfected with plasmids encoding F435-KRAB and/or
shVEGF+64, and incubated for 48 h. To induce hypoxic con-
ditions, some cultures were treated with CoCl2 during the last
7 h of incubation, after which the VEGF-A concentration was
measured by ELISA. Under non-hypoxic conditions, cells
secreted 270 (–25) pg/ml of VEGF-A in the absence of the
ZFP-TF and shRNA, and the VEGF-A amount was increased
to 1040 (–48) pg/ml under hypoxic conditions. Hypoxia-
induced VEGF-A production was reduced independently by
F435-KRAB or shVEGF+64, resulting in the secretion of 270
(–12) pg/ml or 300 (–12) pg/ml of VEGF-A, respectively;
these amounts of VEGF-A were similar to those detected in
the non-hypoxic culture (Figure 5). The amount of VEGF-A
produced in the cultures co-transfected with plasmids encod-
ing the ZFP-TF and shVEGF+64 was further reduced to 190
(–5.1) pg/ml. The residual amount of VEGF-A might come
mostly from hypoxia-stimulated, non-transfected cells, which
constituted  10% of the cell population present in the culture.
Taken together, the combined effect of the ZFP-TF and
shVEGF+64 on VEGF-A expression under both normal and
hypoxic conditions suggests that silencing of the VEGF-A
gene using these reagents might be effective for inhibiting
hypoxia-stimulated tumor angiogenesis under pathological
conditions in vivo.
DISCUSSION
Regulation of gene expression is orchestrated at both the
transcriptional and post-transcriptional levels. Two equally
effective technologies, inhibition of gene expression with arti-
ﬁcial ZFP-TFs and RNAi, provide the means by which to
intervene with each of these processes: ZFP transcriptional
repressors down-regulate gene expression at the transcrip-
tional level, and siRNA does so at the post-transcriptional
level.
Growing evidence has emphasized the speciﬁcity and ver-
satility of ZFPs in modulating the expression of myriad target
genes. Recently, Tan et al. showed that regulation of a single
target gene within the entire human genome is achievable
using a 6-ﬁnger ZFP transcriptional repressor that recognize
an 18-bp site in the genome (32). The ability of ZFPs to
activate or repress target gene expression was also exploited
in a recent report, where the method was used to identify novel
functional relationships among genes (33).
However, the ZFP-TF and siRNA technologies have some
serious limitations. It is hard to achieve >10-fold repression of
target gene expression with siRNA alone (34), although in
some isolated siRNA has been shown to yield almost complete
suppressionofexpressionofseriesofDrosophilagenes (35)or
suppression of replication of variant HIV-1 from Magi cells
Figure 5. Inhibition of hypoxia-induced VEGF activation by ZFPs and
shRNAs. 293F cells were transfected with a plasmid encoding a ZFP-TF
(pF435-KRAB), an shRNA expression vector (shVEGF+64) or both, and then
cultivated for 48 h. During the last 7 h some cells were exposed to CoCl2
(800 mM) to induce hypoxia (+). Secreted VEGF-A protein was analyzed by
ELISA. Non-hypoxic ( ) or hypoxic (+) cell cultures transfected with empty
vectors( shRNA+64, F435-KRAB)servedascontrols.Resultsarethemean
values and standard errors of two independent experiments.
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sors usually yield a 2- to 10-fold repression of target mRNA
expression relative to controls (31,32,37). For many practical
applications and for certain research objectives, these moder-
ate levels of gene suppression are sufﬁcient. For other applica-
tions, however, stronger repression is desired.
Unlike RNAi, the construction of ZFP-TFs is still a special-
ized and sophisticated process. However, we note that several
groups reported successful applications of this approach in the
regulation of diverse genes (22–27,31–32,37–42).
In the present study, we clearly show that combining
ZFP-mediated transcriptional regulation and RNAi-mediated
post-transcriptional regulation of gene expression leads to a
dramatic increase in the extent of gene suppression. Our res-
ults with gene expression systems under the control of various
promoters and with the endogenous human VEGF-A gene
strongly suggest that this method is applicable to almost
any gene. For example, efﬁcient suppression of VEGF-A
expression may be useful for the treatment of diseases such
as cancer and age-related macular degeneration (AMD) (43).
In addition, these two independent tools for gene regulation,
when used in combination, should be of great help in func-
tional genomic studies. RNAi tends to induce up-regulation of
interferon-stimulated genes (44) and thus to elicit non-speciﬁc
effects unrelated to the targeted gene of interest(45).Although
single-gene speciﬁcity within the human genome has been
demonstrated with ZFP-TFs that recognize an 18-bp DNA
site (32), ZFPs, especially those that recognize 9- to 12-bp
DNA sites, appear to alter the transcript levels of dozens of
other genes that are not predetermined targets (22). Consid-
ering these so-called ‘off-target’ effects that are associated
with RNAi and ZFP-TFs, use of these two independent tech-
nologies should yield more robust results than either method
alone.Thusresearchersshouldbeabletoassigngenefunctions
with greater conﬁdence. One may also expect that synergistic
suppression of a gene of interest via the combined effects of
siRNAs and ZFP-TFs would lead to a more severe change in a
phenotype of interest. This characteristic would then allow
dose–response modes of investigation.
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